Table of Contents:
1 Report Prologue
2 Market Introduction
2.1 Definition
2.2 Scope of Study
2.3 Research Objective
2.4 Assumptions & Limitations
2.4.1 Assumptions
2.4.2 Limitations
2.5 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Increasing Cancer Survival Rate
4.2.2 Growing demand for advanced therapies
4.2.3 Less number of side effects as compared to conventional treatment methods
4.2.4 Changing lifestyle and increasing smoking population in Middle East & Africa
4.3 Restraints
4.3.1 High cost of Cancer biological therapy
4.4 Opportunities
4.4.1 Untapped types of Cancers
4.5 Challenges
4.5.1 Strong competition
5 Market Factor Analysis
5.1 Porter's Five Forces Model
5.1.1 Bargaining power of suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intensity of Rivalry
6 Europe, Middle East and Africa Respiratory Inhalers Market, By Type
6.1 Introduction
6.2 Monoclonal Antibodies
6.3 Conjugated Monoclonal Antibodies
6.4 Cancer Growth Blockers
6.5 Interferons
6.6 Interleukins
6.7 Gene Therapy
6.8 Targeted Drug Delivery
6.9 Colony Stimulating Factor
6.10 Cancer Vaccines
6.11 Others.
8 Europe, Middle East and Africa Cancer Biological Therapy Market, By End User
8.1 Introduction
8.2 Hospitals & Clinics
8.3 Laboratories
8.4 Cancer Research Centers
8.5 Others
9 Europe, Middle East and Africa Cancer Biological Therapy Market, By Region
9.1 Introduction
9.2 Europe
9.2.1 Western Europe
9.2.1.1Germany
9.2.1.2 France
9.2.1.3 UK
9.2.1.4 Italy
9.2.1.5 Spain
9.2.2 Rest Of Europe
9.2 Middle East
9.2.2.1 Qatar
9.2.2.2 UAE
9.2.2.3 Kuwait
9.2.2.4 Bahrain
9.2.2.5 Oman
9.2.2.6 Saudi Arabia
10 Competitive Landscape
10.1 Company Share Analysis
12 Company Profiles
11.1 Amgen Inc.
11.1.1 Company Overview
11.1.2 Product/Business Overview
11.1.3 Adherium Health: Financials
11.1.4 Key Developments
11.1.5 SWOT Analysis
11.2 Bristol-Myers Squibb
11.2.1 Company Overview
11.2.2 Product overview
11.2.3 Financial Overview
11.2.4 Key Developments
11.2.5 SWOT Analysis
11.3 Celgene Corporation
11.3.1 Company Overview
11.3.2 Product Overview
11.3.3 Financial Overview
11.3.4 Key Development
11.3.5 SWOT Analysis
11.4 ELI Lilly and Company
11.4.1 Company Overview
11.4.2 Product Overview
11.4.3 Financial Overview
11.4.4 Key Developments
11.4.5 SWOT Analysis
11.5 EnGeneIC Ltd.
11.5.1 Company Overview
11.5.2 Product overview
11.5.3 Financial Overview
11.5.4 Key Developments
11.5.5 SWOT Analysis
11.6 EnGeneIC Ltd.
11.6.1 Company Overview
11.6.2 Product Overview
11.6.3 Propeller Health: Financials
11.6.4 Key Developments
11.6.5 SWOT Analysis
11.7 EnGeneIC Ltd.
11.7.1 Company Overview
11.7.2 Product Overview
11.7.3 Financial Overview
11.7.4 Key Developments
11.7.5 SWOT Analysis
11.8 F. Hoffmann-La Roche AG
11.8.1 Company Overview
11.8.2 Product Overview
11.8.3 Financial Overview
11.8.4 Key Developments
11.8.5 SWOT Analysis
11.9 Merck & Co. Inc.,
11.9.1 Company Overview
11.9.2 Product Overview
11.9.3 Financial Overview
11.9.4 Key Developments
11.9.5 SWOT Analysis
11.10 Novartis
11.10.1 Company Overview
11.10.2 Product Overview
11.10.3 Financial Overview
11.10.4 Key Developments
11.10.5 SWOT Analysis
11.11 Pfizer Inc,
11.11.1 Company Overview
11.11.2 Product Overview
11.11.3 Financial Overview
11.11.4 Key Developments
11.11.5 SWOT Analysis
11.12 Seattle Genetics Inc.
11.12.1 Company Overview
11.12.2 Product Overview
11.12.3 Financial Overview
11.12.4 Key Developments
11.12.5 SWOT Analysis
11.13 Teva Pharmaceutical Industries Ltd.
11.13.1 Company Overview
11.13.2 Product Overview
11.13.3 Financial Overview
11.13.4 Key Developments
11.13.5 SWOT Analysis